Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) resulting in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.
Hereditary Angioedema Market Insight
Hereditary Angioedema Market Size in 7MM in 2017 was USD 1,741.75 million
Hereditary Angioedema Market Drivers
- Rising Prevalence
- Introduction of Oral Therapy
- Increase in R&D
Hereditary Angioedema Market Barriers
- Misdiagnosis and under-diagnosis
- High treatment Cost
Hereditary Angioedema market overall has been segmented into two treatment strategies that are commonly used for HAE as on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible and further as long-term prophylaxis of attacks. Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks.
Over recent years, significant advances have been made about HAE management, and the potential is greater than ever before for affected patients to move closer to living a life that is not overshadowed by disease morbidity. A range of effective therapies have become available, and treatment can now be managed at home by most patients, even with injectable agents. A growing understanding of the underlying pathophysiology of HAE has facilitated the development of several targeted therapies, and ongoing progress in this area will likely continue to improve prophylactic options for HAE as well as refine the disease, particularly in recently identified subtypes with normal C1 inhibitor. Additional laboratory and clinical research may identify biomarkers useful in predicting clinical phenotypes and/or response to various therapeutic agents.
The landscape of therapeutic options for Hereditary Angioedema patients has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration.
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Hereditary Angioedema
3. Competitive Intelligence Analysis for Hereditary Angioedema
4. Hereditary Angioedema : Market Overview at a Glance
4.1. Hereditary Angioedema Total Market Share (%) Distribution in 2017
4.2. Hereditary Angioedema Total Market Share (%) Distribution in 2030
5. Hereditary Angioedema : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hereditary Angioedema Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hereditary Angioedema Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Hereditary Angioedema Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hereditary Angioedema Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Hereditary Angioedema Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Hereditary Angioedema Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Hereditary Angioedema Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hereditary Angioedema Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Hereditary Angioedema Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hereditary Angioedema Treatment and Management
8.2. Hereditary Angioedema Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hereditary Angioedema Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Hereditary Angioedema : Seven Major Market Analysis
13.1. Key Findings
13.2. Hereditary Angioedema Market Size in 7MM
13.3. Hereditary Angioedema Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hereditary Angioedema Total Market Size in the United States
15.1.2. Hereditary Angioedema Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hereditary Angioedema Total Market Size in Germany
15.3.2. Hereditary Angioedema Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hereditary Angioedema Total Market Size in France
15.4.2. Hereditary Angioedema Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hereditary Angioedema Total Market Size in Italy
15.5.2. Hereditary Angioedema Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hereditary Angioedema Total Market Size in Spain
15.6.2. Hereditary Angioedema Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hereditary Angioedema Total Market Size in the United Kingdom
15.7.2. Hereditary Angioedema Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hereditary Angioedema Total Market Size in Japan
15.8.3. Hereditary Angioedema Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hereditary Angioedema
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/